The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: the Italian pediatric oncology view

References

• Ferrari A Sultan I, Rodriguez-Galindo C et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr. Blood Cancer57(6), 943–949 (2011).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer101, 627–634 (2004).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev. Anticancer Ther.5(2), 307–318 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrari A. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas. Expert Rev. Anticancer Ther.8(6), 929–938 (2008).
   PubMed Web of Science ®Google Scholar
• Okcu MF, Munsell M, Treuner J et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J. Clin. Oncol.21, 1602–1611 (2003).
   PubMed Web of Science ®Google Scholar
• Brecht IB, Ferrari A, Int-Veen C et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: discussion on the role of adjuvant therapies. Pediatr. Blood Cancer46, 11–17 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bisogno G, Alaggio G et al. Synovial sarcoma of children and adolescents: the prognostic role of axial sites. Eur. J. Cancer44, 1202–1209 (2008).
   PubMed Web of Science ®Google Scholar
• Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children’s Cancer and Leukaemia Group between 1991 and 2006. Pediatr. Blood Cancer55, 85–90 (2010).
   PubMed Web of Science ®Google Scholar
• Orbach D, Dowell HM, Rey A et al. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) Working Group. Pediatr. Blood Cancer57(7), 1130–1136 (2011).
   PubMed Web of Science ®Google Scholar
• Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet350, 1647–1654 (1997).
   PubMed Web of Science ®Google Scholar
• Sultan I, Rodriguez-Galindo C, Saab R et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology and End Results Program, 1983 to 2005: an analysis of 1268 patients. Cancer115, 3537–3547 (2009).
   PubMed Web of Science ®Google Scholar
• Lewis JJ, Antonescu CR, Leung DH et al. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumours of the extremity. J. Clin. Oncol.18, 2087–2094 (2000).
   PubMed Web of Science ®Google Scholar
• Trassard M, Le Doussal V, Hacene K et al. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J. Clin. Oncol.19, 525–534 (2001).
   PubMed Web of Science ®Google Scholar
• Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann. Oncol.16(3), 437–444 (2005).
   PubMed Web of Science ®Google Scholar
• Eilber FC, Brennan MF, Eilber FR et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann. Surg.246(1), 105–113 (2007).
   PubMed Web of Science ®Google Scholar
• Canter RJ, Qin LX, Maki RG et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin. Cancer Res.14(24), 8191–8197 (2008).
   PubMed Web of Science ®Google Scholar
• Italiano A, Penel N, Robin YM et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann. Oncol.20(3), 425–430 (2009).
   PubMed Web of Science ®Google Scholar
• Palmerini E, Staals EL, Alberghini M et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer115(13), 2988–2998 (2009).
   PubMed Web of Science ®Google Scholar
• Al-Hussaini H, Hogg D, Blackstein ME et al. Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma2011, 231789 (2011).
   PubMedGoogle Scholar
• Guadagnolo BA, Zagars GK, Ballo MT et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.69(4), 1173–1180 (2007).
   PubMed Web of Science ®Google Scholar
• Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer103, 1891–1897 (2005).
   PubMed Web of Science ®Google Scholar
• Burke ME, Albritton K, Marina N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer110, 2385–2393 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Bleyer A. Participation of adolescents with cancer in clinical trials. Cancer Treat. Rev.33, 603–608 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M, Meazza C et al. Adult-type soft tissue sarcomas in pediatric age: experience at the Istituto Nazionale Tumori in Milan. J. Clin. Oncol.23, 4021–4030 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Dileo P, Casanova M et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer98, 571–580 (2003).
   PubMed Web of Science ®Google Scholar
• Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J. Clin. Oncol.27(20), 3391–3397 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev. Anticancer Ther.5(2), 283–294 (2005).
   PubMed Web of Science ®Google Scholar
• Raney RB, Anderson JR, Barr FG et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J. Pediatr. Hematol. Oncol.23(4), 215–220 (2001).
   PubMed Web of Science ®Google Scholar
• Stevens MC, Rey A, Bouvet N et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology – SIOP Malignant Mesenchymal Tumor 89. J. Clin. Oncol.23(12), 2618–2628 (2005).
   PubMed Web of Science ®Google Scholar
• Arndt CA, Stoner JA, Hawkins DS et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children’s Oncology Group Study D9803. J. Clin. Oncol.27, 5182–5188 (2009).
   PubMed Web of Science ®Google Scholar
• Bisogno G, De Rossi C, Gamboa Y et al. Improved survival for children with parameningeal rhabdomyosarcoma: results from the AIEOP soft tissue sarcoma committee. Pediatr. Blood Cancer50, 1154–1158 (2008).
   PubMed Web of Science ®Google Scholar
• Sultan I, Ferrari A. Selecting multimodal therapy for rhabdomyosarcoma. Expert Rev. Anticancer Ther.10(8), 1285–1301 (2010).
   PubMed Web of Science ®Google Scholar
• Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J. Clin. Oncol.24, 3844–3851 (2006).
   PubMed Web of Science ®Google Scholar
• Joshi D, Anderson JR, Paidas C et al. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr. Blood Cancer42, 64–73 (2004).
   PubMed Web of Science ®Google Scholar
• Oberlin O, Rey A, Lyden E et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J. Clin. Oncol.26, 2384–2389 (2008).
   PubMed Web of Science ®Google Scholar
• Bisogno G, Compostella A, Ferrari A et al. Rhabdomyosarcoma in adolescents: a report from the AIEOP Soft Tissue Sarcoma Committee. Cancer doi:10.1002/cncr.26355 (2011) (Epub ahead of print).
   Google Scholar
• Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J. Clin. Oncol.28, 4790–4799 (2010).
   PubMed Web of Science ®Google Scholar
• Hawkins WG, Hoos A, Antonescu CR et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer91, 794–803 (2001).
   PubMed Web of Science ®Google Scholar
• Esnaola NF, Rubin BP, Baldini EH et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Cancer91, 794–803 (2001).
   PubMed Web of Science ®Google Scholar
• Little DJ, Ballo MT, Zagars GK et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer95, 377–388 (2002).
   PubMed Web of Science ®Google Scholar
• La Quaglia MP, Heller G, Ghavimi F et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer73, 109–117 (1994).
   PubMed Web of Science ®Google Scholar
• Bleyer A, Tejeda H, Murphy SB et al. National cancer clinical trials: children have equal access; adolescents do not. J. Adolesc. Health21, 366–373 (1997).
   PubMed Web of Science ®Google Scholar
• Liu L, Krailo M, Reaman GH, Bernstein L. Childhood cancer patients’ access to cooperative group cancer programs: a population-based study. Cancer97(5), 1339–1345 (2003).
   PubMed Web of Science ®Google Scholar
• Bleyer A, Barr R. Highlights and challenges. In: Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival 1975–2000. Bleyer A, O’Leary M, Barr R, Ries LAG (Eds). National Cancer Institute, NIH Pub. No. 06-5767, Bethesda, MD, USA (2006).
   Google Scholar
• Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer107, 1645–1655 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Montello M, Budd T et al. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr. Blood Cancer50, 1101–1104 (2008).
   PubMed Web of Science ®Google Scholar
• Fern L, Davies S, Eden T et al. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. Br. J. Cancer99(12), 1967–1974 (2008).
   PubMed Web of Science ®Google Scholar
• Desandes E, Lacour B, Sommelet D et al. Cancer adolescent pathway in France between 1988 and 1997. Eur. J. Oncol. Nurs.11(1), 74–81 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Dama E, Pession A et al. Adolescents with cancer in Italy: entry into the national cooperative paediatric oncology group AIEOP trials. Eur. J. Cancer45(3), 328–334 (2009).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Meazza C, Vajna de Pava M et al. Two cases of adolescents with paratesticular rhabdomyosarcoma inadequately treated: the problem of referral. J. Adol. Young Adult Oncol. (2011) (In Press).
   PubMedGoogle Scholar
• Ferrari A, Miceli R, Casanova M et al. Symptom interval in children and adolescents with soft tissue sarcomas. Cancer116, 177–183 (2010).
   PubMed Web of Science ®Google Scholar
• Dang-Tan T, Trottier H, Mery LS et al. Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr. Blood Cancer51(4), 468–474 (2008).
   PubMed Web of Science ®Google Scholar
• Martin S, Ulrich C, Munsell M, Taylor S, Lange G, Bleyer A. Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist12, 816–824 (2007).
   PubMed Web of Science ®Google Scholar
• Ziv A, Boulet JR, Slap GB. Utilization of physician offices by adolescents in the United States. Pediatrics104, 35–42 (1999).
   PubMed Web of Science ®Google Scholar
• Andersen BL, Cacioppo JT. Delay in seeking a cancer diagnosis: delay stages and psychophysiological comparison processes. Br. J. Psychol.34(Pt 1), 33–52 (1995).
   Web of Science ®Google Scholar
• Morgan S, Davies S, Palmer S, Plaster M. Sex, drugs, and rock ‘n’ roll: caring for adolescents and young adults with cancer. J. Clin. Oncol.28(32), 4825–4830 (2010).
   PubMed Web of Science ®Google Scholar
• Gronchi A, Miceli R, Colombo C et al. Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. Ann. Oncol.22(7), 1675–1681 (2011).
   PubMed Web of Science ®Google Scholar
• Gronchi A, Frustaci S, Mercuri M et al. Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: a Phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS). J. Clin. Oncol.28, 15s (2010) (Abstract 10003).
   PubMed Web of Science ®Google Scholar
• Stacchiotti S, Negri T, Zaffaroni N et al. Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann. Oncol.22(7), 1682–1690 (2011).
   PubMed Web of Science ®Google Scholar
• Gronchi A, Bui BN, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann. Oncol. doi:10.1093/annonc/mdr265 (2011) (Epub ahead of print).
   Google Scholar
• Bleyer A, Morgan S, Barr R. Proceedings of a workshop: bridging the gap in care and addressing participation in clinical trials. Cancer107(Suppl. 7), 1656–1658 (2006).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Thomas DM, Franklin A et al. Starting an AYA program: some success stories and some obstacles to overcome. J. Clin. Oncol.28(32), 4850–4857 (2010).
   PubMed Web of Science ®Google Scholar
• Whiteson M. The Teenage Cancer Trust –advocating a model for teenage cancer services. Eur. J. Cancer39, 2688–2693 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis IJ, Fallon S, van Dongen-Melman J, Barr R. Cancer and the adolescent: the Second Teenage Cancer Trust International Conference, Royal College of Physicians, London, England, March 2001. Med. Pediatr. Oncol.39(3), 198–201 (2002).
   PubMedGoogle Scholar
• Eden T. Keynote comment: challenges of teenage and young-adult oncology. Lancet Oncol.7, 612–613 (2006).
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Closing The Gap: Research And Care Imperatives For Adolescents And Young Adults With Cancer. NIH publication 06-6067, Bethesda, MD, USA (2006).
   Google Scholar
• Mathews-Bradshaw B, Johnson R, Kaplan S et al. The history and accomplishments of the LIVESTRONG Youg Adult Alliance. J. Adol. Young Adult Oncol.1(1), 43–47 (2011).
   PubMed Web of Science ®Google Scholar
• Barr R, Eden T. International working group on adolescent/teenage and young adult oncology. Pediatr. Blood Cancer50, 1089 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrari A, Aricò M, Dini G et al. Upper-age limits for accessing pediatric oncology centers in Italy: a barrier preventing adolescents with cancer from entering national cooperative AIEOP trials. Pediatr. Hematol. Oncol. doi:10.3109/08880018.2011.572963 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Ferrari A, Clerici CA, Casanova M et al. The Youth Project at the Istituto Nazionale Tumori in Milan. Tumori (2011) (In Press).
   Google Scholar
• Ferrari A. Harmonizing adult and pediatric approaches to the treatment of soft tissue sarcoma. Expert Rev. Anticancer Ther.9(11), 1541–1543 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas DM, Albritton KH, Ferrari A. Adolescent and young adult oncology: an emerging field. J. Clin. Oncol.28(32), 4781–4782 (2010).
   PubMed Web of Science ®Google Scholar
• Bleyer A. The Quid Pro Quo of pediatric versus adult services for older adolescent cancer patients. Pediatr. Blood Cancer54(2), 238–241 (2010).
   PubMed Web of Science ®Google Scholar
• Klein-Geltink J, Shaw AK, Morrison HI et al. Use of paediatric versus adult oncology treatment centres by adolescents 15–19 years old: the Canadian Childhood Cancer Surveillance and Control Program. Eur. J. Cancer41(3), 404–410 (2005).
   PubMed Web of Science ®Google Scholar
• Boissel N, Auclerc MF, Lheritier V et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J. Clin. Oncol.21, 774–780 (2003).
   PubMed Web of Science ®Google Scholar
• Ramanujachar R, Richards S, Hann I, Webb D. Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatr. Blood Cancer43(6), 748–756 (2006).
   Web of Science ®Google Scholar
• de Bont JM, van der Holt B, Dekker AW et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric versus adult ALL protocols in The Netherlands. Leukemia18, 2032–2053 (2004).
   PubMed Web of Science ®Google Scholar
• Paulussen S, Ahrens S, Juergens HF. Cure rates in Ewing tumor patients aged over 15 years are better in pediatric oncology units. Results of GPOH CESS/EICESS studies. Proc. Am. Soc. Clin. Oncol.22, 816 (2003).
   Google Scholar